Head to Head Contrast: Berto Acquisition (NASDAQ:TACO) vs. Quest Diagnostics (NYSE:DGX)

Berto Acquisition (NASDAQ:TACO) and Quest Diagnostics (NYSE:DGX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Profitability

This table compares Berto Acquisition and Quest Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Berto Acquisition	N/A	N/A	N/A
Quest Diagnostics	9.18%	16.01%	7.27%

Earnings and Valuation

This table compares Berto Acquisition and Quest Diagnostics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Berto Acquisition	N/A	N/A	N/A	N/A	N/A
Quest Diagnostics	$11.04 billion	2.38	$992.00 million	$9.42	25.21

Quest Diagnostics has higher revenue and earnings than Berto Acquisition.

Insider and Institutional Ownership

88.1% of Quest Diagnostics shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Berto Acquisition has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Berto Acquisition and Quest Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Berto Acquisition	1	0	0	0	1.00
Quest Diagnostics	0	7	6	0	2.46

Quest Diagnostics has a consensus target price of $235.31, indicating a potential downside of 0.91%. Given Quest Diagnostics’ stronger consensus rating and higher possible upside, analysts plainly believe Quest Diagnostics is more favorable than Berto Acquisition.

Summary

Quest Diagnostics beats Berto Acquisition on 10 of the 10 factors compared between the two stocks.

About Berto Acquisition

Del Taco Restaurants, Inc. develops, franchises, owns, and operates Del Taco quick-service Mexican-American restaurants in the United States. The company's restaurants offer Mexican inspired and American classic dishes. As of August 31, 2021, it operated approximately 600 restaurants across 16 states. The company was founded in 1964 and is headquartered in Lake Forest, California.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.